Navigation Links
An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes

rly those mentioned in the risk factors and cautionary statements in Item 1A of Merck's Form 10-K for the year ended Dec. 31, 2006, and in its periodic reports on Form 10-Q and Form 8-K, which the Company incorporates by reference.

Prescribing information and patient product information for JANUVIA and JANUMET are attached.

JANUVIA(TM) and JANUMET(TM) are trademarks of Merck & Co., Inc. -0-

JANUVIA(TM)(sitagliptin) Tablets                     9762701


    HIGHLIGHTS OF PRESCRIBING INFORMATION


    These highlights do not include all the information needed to use

JANUVIA safely and effectively. See full prescribing information for

JANUVIA.


    JANUVIA(TM) (sitagliptin) Tablets


    Initial U.S. Approval: 2006


    INDICATIONS AND USAGE


    JANUVIA is indicated as an adjunct to diet and exercise to improve

glycemic control in patients with type 2 diabetes mellitus (type 2

diabetes). JANUVIA is indicated for:


    --  Monotherapy (1.1)


    --  Combination therapy with metformin or a peroxisome

        proliferator-activated receptor gamma (PPAR-gamma) agonist

        (e.g., thiazolidinediones) when the single agent does not

        provide adequate glycemic control. (1.2)


    Important Limitations of Use: JANUVIA should not be used in

patients with type 1 diabetes mellitus (type 1 diabetes) or for the

treatment of diabetic ketoacidosis. (1.3)


    DOSAGE AND ADMINISTRATION


    The recommended dose of JANUVIA is 100 mg once daily as

monotherapy or as combination therapy with metformin or a PPAR-gamma

agonist (e.g., thiazolidinediones). (2.1)


    JANUVIA can be taken with or without food. (2.1)



  Dosage Adjustment in Patients With Moderate, Severe and End Stage

                      Renal Disease (ESRD) (2.2)

----------------------------------------------------------------------

           50 mg once daily                   25 mg once daily

--------------------------------------------------------------------
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
3. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
4. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
5. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
6. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:10/20/2014)... ENGLEWOOD, Colo. , Oct. 20, 2014 /PRNewswire/ ... Inc. (NYSE MKT: AMPE), today announced that its ... the clinical and research potential for its novel ... oxidation-reduction potential (ORP) in the body in response ... clinical value of ORP as a clinical marker ...
(Date:10/20/2014)... , Oct. 20, 2014   BioNano Genomics ... system: the ability to collect human data at 30X depth, ... single chip.  This new capability was established and demonstrated for ... Irys TM System and will be rolled ... months. BioNano will be showcasing this advancement at the ...
(Date:10/20/2014)... 2014 Lpath, Inc. (NASDAQ: ... therapeutics, received official notification from the European Patent Office ... patent supporting its iSONEP™ and ASONEP™ programs. ... No. 2087002, claims compositions of matter related to ... compounds, iSONEP and ASONEP. Sonepcizumab is an antibody ...
Breaking Medicine Technology:Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... Trial to Test Unique Delivery System Using Living Cells ... Texas-based Specialty Biopharmaceutical Company , , ... HEALTHPOINT, Ltd. today announced that it has enrolled the ... II dose response study investigating an experimental, cell-based wound ...
... SAN DIEGO, June 16 Neurocrine Biosciences, Inc. (Nasdaq: ... and Phase II elagolix trials and preclinical work was presented ... 09) in Washington DC, June 10-13, 2009. , , ... results of a Phase I study in which elagolix was ...
Cached Medicine Technology:HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study 2HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study 3HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study 4Neurocrine Biosciences Presents Elagolix Data 2Neurocrine Biosciences Presents Elagolix Data 3Neurocrine Biosciences Presents Elagolix Data 4
(Date:10/20/2014)... 2014 Succeed is proud to announce that ... participated in the Every Body Walk! campaign by ... project that encourages workers to be more active outside of ... which concluded at the end of September, was a friendly ... metro areas. Participating companies gave their staff pedometers and ...
(Date:10/20/2014)... October 20, 2014 Final Cut Pro X ... of the Citrus theme for FCPX filmmakers . , ... to describe the Citrus theme” Says Christina Austin, CEO of ... look so professional.” , Citrus comes with all the tools ... template are: four transitions for added style, a title screen ...
(Date:10/20/2014)... New York, NY (PRWEB) October 20, 2014 ... to be introduced in the U.S., has a lot to ... time when our country recognizes the achievements and contributions of ... marks the anniversary for Punzoné, and today it shares its ... and take a trip to Italy - even if it ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Hastings and ... 30 years of service throughout the greater Phoenix area ... legal representation with regard to catastrophic automobile accidents. Statistics ... the country and throughout Arizona. As such, Hastings and ... for legal representation for those who have been injured ...
(Date:10/19/2014)... New York (PRWEB) October 19, 2014 ... Nations Population Fund, welcomes news of a ceasefire agreement ... the more than 200 girls who were kidnapped from ... girls have languished in captivity long enough, and it ... schools and communities," stated Dr. Osotimehin. , "We owe ...
Breaking Medicine News(10 mins):Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3
... University School of Medicine (BUSM) have discovered new details ... team connected pharmacological properties of the Novartis Pharma AG ... first time after investigating adverse reactions suffered by patients ... osteoporosis. These findings appear online in the Journal ...
... executed a license agreement with The Incubation Factory, St. Louis, ... is pending. The tonometer was developed by a ... Robert Fechtner, MD, director of the glaucoma division at UMDNJ. ... the research team. "We are excited that this ...
... HealthDay Reporter , MONDAY, May 16 (HealthDay News) -- ... "bad" cholesterol levels, and may in fact prompt a very modest ... The finding comes from a six-month examination of the impact ... healthy people in England. , , "The issue is that there ...
... Elsevier, the world-leading publisher of scientific, technical ... launch of Mosby,s Textbook of Dental Nursing. Written ... Assessment Centre for Dental Nurses, Eastman Dental Institute ... of Oral Medicine, Pathology and Microbiology, University of ...
... , WORCESTER, Mass. A new book edited by ... Brook University School of Medicine provides a comprehensive look ... at the leading cause of death---heart disease. "Regenerating the ... is edited by Glenn Gaudette, associate professor of biomedical ...
... institutionalized Romanian children have found that the length of ... correlates with lower IQ and behavioral problems. A ... and Tulane University, shows that early adversity even affects ... as telomeres, and hastening how quickly their cells "age." ...
Cached Medicine News:Health News:NJIT and UMDNJ license personal tonometer technology for innovative glaucoma testing 2Health News:Selenium Supplements Might Give Modest Benefit Against Cholesterol 2Health News:Selenium Supplements Might Give Modest Benefit Against Cholesterol 3Health News:New book explores stem cell therapies for heart disease 2Health News:Deprivation and neglect found to age children's chromosomes 2Health News:Deprivation and neglect found to age children's chromosomes 3
Hudson Drill hand drill....
Hudson Brace, snap lock chuck....
Binocular operation microscope with innovative mechanism for smooth operation....
... has pioneered the development of ... system, an innovative solution that ... efficient and less invasive. The ... the OME-7000 surgical microscope, the ...
Medicine Products: